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Introduction
Pleural effusions affect approximately 1.5 million patients 
per year in the United States and remain one of the most 
commonly encountered entities by the chest physician (1,2). 
The diagnostic approach to pleural effusions has historically 
involved thoracentesis and pleural fluid analysis utilizing 
Light’s criteria, followed by increasingly invasive procedures 
such as closed and/or visualized pleural biopsy. These 
procedures remain mainstays in the evaluation of the pleural 
space however in recent years new imaging modalities as 
well as minimally invasive approaches to old techniques 
have added themselves to the clinicians’ armamentarium 
in the diagnosis pleural disease. On the other hand, the 
therapeutic management of pleural disease had seen little 
change in the last 100 years until the recent introduction of 
new high value techniques in the care of pleural infection, 
malignancy and persistent air leaks. In this review will 
address our past and current practices in the diagnosis and 
treatment of pleural disease, highlighting recent advances 
and potential future innovations. 
Thoracic imaging in pleural disease 
Chest radiography
The investigation and management of pleural disease 
has historically relied heavily on thoracic imaging. Chest 
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radiographs (CXR) particularly the erect posterior-anterior 
view are frequently the first imaging used to assess the 
pleural space. Lateral and decubitus radiographs are now 
performed less often to the increasing availability and 
superiority of point-of-care ultrasound (US) and computed 
tomography (CT) (3-5).
Ultrasonography
Thoracic US has become increasingly the modality of 
choice for the evaluation of pleural disease. Once adequate 
education has been achieved US has proven itself to be 
portable, easy to use, within improved patient safety and 
increased diagnostic accuracy (3). The data now strongly 
supports an improvement in patient safety with the use 
of US when performing thoracentesis and should be 
considered standard of care (6-8). Ultrasonography has also 
shown itself to be superior to portable CXR in the detection 
of pleural effusions, estimation of volume, prediction of the 
fluid characteristics and in guided intervention (4,9-11) 
(Figure 1). When compared with the historic practice of 
CXR and physical examination prior to thoracentesis, 
US has been shown to be far superior in identifying an 
appropriate needle entrance point, even in the hands of 
‘experts’ in diagnosis and management of chest disease (12). 
Several studies also suggest a lack of inferiority of US to 
CT when assessing the pleural space and that the real-time 
imaging may add additional information not available on 
CT (13).
Computed and positron-emission tomography
The use of thoracic CT in the diagnosis and management of 
pleural disease has become increasingly common place. Use 
of delayed intravenous contrast is often used to optimize 
pleural soft-tissue enhancement (3,14,15). High-resolution 
CT scanning can be used in the detection of pleural 
plaques and should be performed with 1 mm and high 
spatial resolution reconstruction algorithm. One important 
characteristic of the thoracic CT is its ability to not only 
evaluate the pleural space but to also reveal underlying lung 
parenchymal, mediastinal and/or hilar disease. Thoracic 
CT has also been adapted to procedural performance. CT-
guided placement of chest drains, thoracentesis and in the 
biopsy of the parietal pleura, have been well documented 
with excellent diagnostic yields and safety (16-19) (Figure 2). 
Positron-emission tomography in combination with CT has 
been shown to be useful in patients with focal or generalized 
pleural thickening suspicious for malignancy (15). 
The major limitation of CT and positron emission 
tomography (PET) imaging is its lack of portability to the 
patient’s bedside, with the inherent difficulty of performing 
repeated examinations and associated radiation exposure.
Magnetic resonance imaging
Historically thought to have a limited role, magnetic 
resonance imaging (MRI) has begun to find its place in 
the diagnosis and management of pleural disease. New 
advances in MRI technology has allowed for improved 
image quality of the thorax and specifically the pleural 
space (20). Improvements in MRI signal and interpretation 
has led to the ability to differentiate between such entities 
as transudates, exudates, hematoma, malignant pleural 
implants and chest wall invasion. Differentiation between 
causes of exudative effusions such as parapneumonic vs. 
malignant effusion vs. empyema remains challenging. 
Recent studies into functional MRI have led to the 
suggestion that it can be used as a modality to assess for 
treatment response of malignant pleural disease (21).
Pleural fluid analysis
Fluid analysis has long been the initial step in evaluation of 
pleural disease presenting as an idiopathic effusion. First 
reported in 1972, Light’s criteria gave clinicians an easy set 
of criteria by which to classify pleural effusions as either 
transudate or exudate (22). Light’s criteria has since been 
criticized for over classifying exudates and the reliance on 
serum measurements. This has led to a series of proposed 
modifications that include measurement of pleural fluid 
Figure 1 Ultrasound image of a pleural effusion, note the 
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Figure 2 Chest computed tomography. (A) Empyema of the right pleural space; (B) CT-guided chest tube (arrows) placed into the right 
pleural space with drainage.
cholesterol and albumin. In 1987, Hamm et al. were the 
first to present the measurement of cholesterol as a marker 
for differentiation between transudative and exudative 
pleural effusion (23). This has been followed by multiple 
studies including a meta-analysis confirming the utility of 
cholesterol as an aid in pleural fluid characterization 
(24-26). The serum to protein albumin gradient has also 
show itself to be useful in the characterization of pleural 
fluid (27). This measure appears to be quite helpful in 
properly evaluating those patients with a clinical picture 
consistent with a transudative process but found to have an 
exudate when their pleural fluid is analyzed, the so called 
“false-exudate”, commonly seen in patients with congestive 
heart failure who have received diuretic therapy (28). The 
amino-terminal fragment of pro-brain natriuretic peptide 
(NT-proBNP) has also been evaluated as an adjunct test to 
aid in the differentiation of pleural effusions when a “false-
exudate” is suspected. Porcel et al., evaluated 93 patients 
with pleural effusion and found that using a cut-off of 
1,500 pg/mL, the receiver operating characteristic curve 
for the diagnosis of heart failure effusion was 0.931 for 
NT-proBNP in the pleural fluid. This makes NT-proBNP a 
very useful marker when faced with the diagnostic dilemma 
of the “false-exudate”, however, it tends to correlate 
extremely well with serum NT-BNP, and thus serum 
NT-BNP can be used to make the diagnosis (29,30).
Parapneumonic effusions and empyema
Despite advances in the treatment of pneumonia, the 
incidence of pleural disease related to infection continues 
rise (31-33). Of patients presenting with a parapneumonic 
effusion, 10% will develop an empyema and 20% will 
require surgical intervention (34). Typical first steps 
when being presented with a pneumonia and suspected 
parapneumonic pleural process are sampling of the effusion 
to further characterize it as simple, complex or empyema 
and the administration of broad spectrum antibiotics 
tailored to the local microbiome. This is often followed by 
placement of a chest drain in an attempt to fully drain the 
pleural space and to achieve source control. Controversy 
exists around the management of pleural infection when 
failure to fully drain the pleural space occurs after chest 
drain placement. Surgical intervention in the setting of 
pleural infection that has failed medical therapy has been 
recommended by the current guidelines and has been 
considered first line therapy in the United States (34). In 
the MIST2 trial, Rahman et al., evaluated the effect of tPA 
and DNase alone and in combination on drainage of pleural 
infection by way of radiographic improvement. They were 
able to show a significant improvement in the CXR of those 
patients who received combination versus single agent or 
placebo fibrinolysis (35). Further study of this subject is 
necessary to better understand this technique’s effect on 
mortality, morbidity and length of stay. In addition, a group 
of patients in the MIST2 trial went on to surgery after 
fibrinolytic administration, an issue that warrants further 
study in an effort to better risk stratify patients prior to 
intervention. 
The first attempt at pre-interventional risk stratification 
was recently published by Rahman et al., who developed 
a scoring system (RAPID) to aimed to identifying those 
patients at high risk of death from pleural infection (36). 
White et al., retrospectively evaluated the RAPID score of 
A B
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187 patients in an effort at assess increased risk of mortality 
at 3 months, 1, 3 and 5 years respectively. They reported a 
significant in increase mortality among the medium- and 
high-risk groups at all of the measured time points when 
compared to the low-risk group (37).
Medical thoracoscopy 
Single port medical thoracoscopy has become increasingly 
common place in its use by pulmonologists in diagnosis 
and treatment of pleural disease. Medical thoracoscopy 
has gone from supplanting closed pleural biopsy in the 
diagnosis of malignant and infectious diseases (38,39) 
to including such interventions as talc poudrage in the 
setting of pneumothorax and malignant pleural effusion 
and in the treatment of complex parapneumonic effusion 
and empyema. In addition, semi-rigid thoracoscopes 
have been shown to have similar diagnostic yields to rigid 
thoracoscopes despite smaller biopsy size (40,41).
Empyema 
In the United States and UK, invasive surgical intervention 
for complex parapneumonic effusion and empyema not 
responding to medical therapy remains the provenance 
of the thoracic surgeon. Three non-randomized, non-
comparator case series have recently reported high ‘success 
rates’ and low or no complications in patients undergoing 
medical thoracoscopy for pleural infection (42). These 
case series present data that indicates a potential role for 
medical thoracoscopy in the treatment these diseases, 
however prospective randomized data is required before the 
applicability of medical thoracoscopy to pleural infections 
can be recommended. 
Pneumothorax
The treatment of primary spontaneous pneumothorax via 
semi-rigid or rigid medical thoracoscopy with talc poudrage 
has gained increasing acceptance a therapeutic modality 
in those patients with persistent air leaks or recurrent 
pneumothorax, with a reported 93% durable success rate 
and potential cost savings when compared with standard 
chest tube drainage (43,44). However, surgical intervention 
utilizing single lung ventilation and mechanical vs. talc 
pleurodesis remains the “gold standard” for treatment of 
this disease process. 
In an elegant study, Noppen et al. performed a comparison 
of white light medical thoracoscopy with thoracoscopy 
utilizing fluorescein-enhanced autofluorescence to assess 
pleural integrity in patients with primary spontaneous 
pneumothorax (PSP) compared to controls. In those 
patients with primary spontaneous pneumothorax, 
autofluorescence showed abnormalities of the pleura 
in those areas that appeared normal under white light, 
suggesting that significant parenchymal abnormalities 
outside of readily visible blebs and bullae were present 
and likely responsible for the recurrent nature of the 
disease (45). As such, evidence suggests significantly lower 
recurrence rates when pleurodesis is performed as opposed 
to bullectomy alone.
Persistent air leaks
Bronchopleural fistula (BPF)/alveolar-pleural fistula or 
persistent air leak (PAL) is a cause of significant morbidity 
and mortality after parenchymal lung resection, spontaneous 
pneumothorax, and/or chronic suppurative lung disease. 
The incidence of BPF post lobectomy or pneumonectomy 
has been reported to be as high as 4.5%, with an associated 
mortality of up to 27%. In those patients with BPF, up to 
90% require a repeat surgical procedure (46). PAL can lead 
to prolonged hospitalization and complications that result 
in increased health care costs (47).
Many non-surgical methods have been attempted to 
treat post-resection PAL with varying degrees of success. 
The most conservative treatment is prolonged chest 
tube placement with either a pleural drainage system or 
Heimlich valve. Pleural-based methods include pleurodesis 
via mechanical, chemical, and autologous means (48-50). 
These methods of pleurodesis have not been shown to have 
reliable efficacy, require that the lung has fully re-
expanded and carry with them their own associated 
risks (51). Bronchoscopic attempts to treat PAL have 
include vascular coils, fibrin or tissue glue, spigots, stents, 
gel foam, silver nitrate, and autologous endobronchial blood 
patch (52,53). While these methods have all shown promise, 
each has its limitations, and none have shown significant 
efficacy to replace surgical intervention in the treatment of 
post-resection PAL. 
Endobronchial valves
Two one-way endobronchial airway valves (EBV) placed 
for the purpose of promoting segmental lung atelectasis 
currently exist. The Emphasys® Zephyr® Endobronchial 
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valve (ZEBV, Pulmonx Inc., Neuchatel Switzerland) is a 
2nd generation device that consists of a silicone “duck bill” 
attached to a nitinol skeleton and is reported to have a lower 
airway resistance profile than previous models (Figure 3). 
The Intrabronchial Valve, (IBV, Spiration Inc., Redmond, 
WA, USA) uses a polymer membrane suspended from a 
nitinol framework shaped like an umbrella to act as a one-
way valve (Figure 4). 
EBV were originally developed for the purpose 
of performing bronchoscopic lung volume reduction 
(BLVR) to treat patients with heterogeneous emphysema 
and hyperinflation. Though neither of the airway valve 
technologies has received FDA approval for BLVR they 
have been used successfully in the closure of persistent post-
surgical BPF. The IBV was approved by the FDA in 2006 
for use under the Humanitarian Device Exemption program 
for patients with PAL after lung parenchymal resection (54).
EBV can be placed via flexible bronchoscopy under 
general or moderate anesthesia. A pleural drainage system 
must be in place to evaluate changes in air leak during the 
procedure. Prior to EBV placement, balloon occlusion is 
used to identify the bronchus or bronchi involved. The 
EBV is then deployed into the airway through the working 
channel of the bronchoscope and the patient’s chest drain 
is observed for cessation or decrease in the PAL. The EBV 
are subsequently removed 4-6 weeks after placement and 
resolution of the air leak in order to minimize the risk of 
infection, granulation, migration, or expectoration of the 
valve (55).
The use of endobronchial valves for treatment of 
PAL was first described in three case reports in 2005 and 
2006 (56-58). In all of these cases EBV were used to treat 
persistent post-operative air leaks, which had been present 
in one case for over 6 years, and resulted in resolution of 
the PAL. Since these first reports, a number of case series 
and reports have been published describing the use of EBV 
to treat PAL in post-operative patients and those with 
spontaneous pneumothorax with low complication rates 
(59-67). These case series suggest that EBV placement is 
a safe and effective therapy for BPF and PAL after lung 
resection, spontaneous pneumothorax, and suppurative lung 
or pleural infection.
The use of EBV in the critical care setting has also 
been reported, including in patients requiring mechanical 
ventilation, extracorporeal membrane oxygenation 
(ECMO), and as a bridge to lung transplantation (68-70).
Development and regular use of less invasive strategies 
for the management of BPF/PAL in patients has the 
potential to improve patient morbidity. Studies to date, 
however, are limited by small sample size and lack of a 
comparison group. Prospective randomized controlled trials 
are needed to assess the efficacy of EBV placement in the 
treatment of BPF/PAL.
Management of malignant pleural effusions
Recent advances in malignant pleural disease has been 
primarily focused on the use of tunneled pleural catheters 
(TPCs) in the management of dyspnea, hospital length of 
stay, quality of life and cost effectiveness of the procedure. 
The catheter is a 15 French fenestrated drain that is inserted 
into the pleural space and then tunneled subcutaneously to 
reduce the risk of infectious complications (Figure 5). The 
majority of these procedures can be done in an outpatient 
setting. Since their introduction, TPCs have become 
increasingly ubiquitous with the palliative management of 
malignant pleural disease. This technology continues to 
be rigorously studied as providers search for less invasive 
management options than classic surgical intervention. 
Shown to be safe and effective in the treatment of malignant 
Figure 3 Illustration of a one-way endobronchial valve—Zephyr™ 
valve. (Picture courtesy of Pulmonx Corp.).
Figure 4 One-way intrabronchial valve—Spiration valve. (Picture 
courtesy of Spiration, Inc.).
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pleural effusions (MPE) (71,72), the study of TPCs has 
turned toward comparisons with invasive surgical techniques 
and chemical pleurodesis. In a study aimed at developing a 
method of “rapid” pleurodesis for the management of MPE, 
thoracoscopy, talc pleurodesis and TPC placement were 
performed simultaneously followed by aggressive outpatient 
TPC drainage (Figure 6). Compared with TPC spontaneous 
pleurodesis rates of 40-60% and a historical length of 
stay (LOS) of 5 days following talc poudrage, pleurodesis 
and length of stay were found to be 92% and a median of 
1.79 days in the “rapid pleurodesis” cohort respectively. 
This pilot study was not powered nor randomized to assess 
a statistical difference between modalities and prospective 
randomized trials are needed (73). Hunt et al., retrospectively 
reviewed 109 patients who underwent thoracoscopy and 
talc poudrage vs. TPC placement for symptomatic MPE. 
Patients undergoing TPC placement had significantly 
shorter LOS and lower rates of reintervention (74). In a 
propensity matched retrospective study comparing TPC to 
thoracoscopy and talc poudrage, Freeman et al., reported 
that patients undergoing TPC placement for MPE had 
significantly shorter LOS, interval to systemic therapy 
and lower rates of operative morbidity (75). Two recent 
prospective studies of MPE treatment comparing TPC 
and talc pleurodesis, via slurry or poudrage, reported 
significantly shorter LOS, improvements in dyspnea, quality 
of life (QOL) and fewer episodes of pleural reintervention 
(76,77). Puri et al., published a cost effectiveness study 
of the treatment of MPE that used decision analysis to 
compare repeated thoracentesis, TPC, bedside talc slurry 
and talc poudrage. They reported that when comparing 
pleurodesis strategies for patients with short expected 
survival time (3 months) TPC was the preferred treatment 
strategy due to decreased cost and improved efficacy. They 
went on to report that for patients with longer expected 
survival times (12 months) that bedside pleurodesis was 
more cost effective (78). Sabur and colleagues published 
the first study specifically examining the effect of TPCs on 
QOL in patients with MPE. They reported that TPCs were 
associated with significant improvements in global health 
status, QOL and dyspnea at 2 weeks follow up from pre-
procedure baseline. Due to the death of 45% of the patients 
enrolled, measures at 14 weeks were improved but did not 
reach statistical significance (79).
Figure 5 (A) Tunneled pleural catheter -Pleurx™; (B) Tunneled pleural catheter connected to a vacuum drainage bottle. (Pictures courtesy 
of CareFusion, Inc.).
Figure 6 Rapid pleurodesis. Medical thoracoscopy with tunneled 
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Conclusions
Pleural effusions remain one of the most frequently 
encountered disease processes by the thoracic medicine 
practitioner. Though this disease process continues to 
challenge physicians, advances have been made in the 
diagnosis and management of pleural effusion. Previous 
methods of evaluating the etiology of pleural disease 
remain useful and have been modified improving their 
sensitivity and specificity. Imaging of the pleural space has 
continued to advance diagnostic capability and advances in 
the treatment and diagnosis of pleural infection have been 
profound. With these advances come the need for improved 
risk stratification for patients with pleural infection. 
Malignant pleural effusion management has seen great 
strides with the development of TPC allowing patients 
to palliate themselves at home and avoid further invasive 
procedures. These improvements in the diagnosis and 
treatment of pleural effusions have set the stage for future 
advances in our understanding of pleural pathophysiology 
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